JP2021515039A5 - - Google Patents

Info

Publication number
JP2021515039A5
JP2021515039A5 JP2020567470A JP2020567470A JP2021515039A5 JP 2021515039 A5 JP2021515039 A5 JP 2021515039A5 JP 2020567470 A JP2020567470 A JP 2020567470A JP 2020567470 A JP2020567470 A JP 2020567470A JP 2021515039 A5 JP2021515039 A5 JP 2021515039A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
asthma
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021515039A (ja
JP7572041B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/019872 external-priority patent/WO2019169015A1/en
Publication of JP2021515039A publication Critical patent/JP2021515039A/ja
Publication of JP2021515039A5 publication Critical patent/JP2021515039A5/ja
Application granted granted Critical
Publication of JP7572041B2 publication Critical patent/JP7572041B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567470A 2018-02-27 2019-02-27 重症喘息を処置するための組成物および方法 Active JP7572041B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636092P 2018-02-27 2018-02-27
US62/636,092 2018-02-27
PCT/US2019/019872 WO2019169015A1 (en) 2018-02-27 2019-02-27 Anti cd6 antibodies for treating severe asthma

Publications (3)

Publication Number Publication Date
JP2021515039A JP2021515039A (ja) 2021-06-17
JP2021515039A5 true JP2021515039A5 (cg-RX-API-DMAC7.html) 2022-03-07
JP7572041B2 JP7572041B2 (ja) 2024-10-23

Family

ID=65724591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020567470A Active JP7572041B2 (ja) 2018-02-27 2019-02-27 重症喘息を処置するための組成物および方法

Country Status (14)

Country Link
US (2) US20210380711A1 (cg-RX-API-DMAC7.html)
EP (1) EP3759140A1 (cg-RX-API-DMAC7.html)
JP (1) JP7572041B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200128415A (cg-RX-API-DMAC7.html)
CN (1) CN112424226B (cg-RX-API-DMAC7.html)
AU (1) AU2019228508A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020017445A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091920A1 (cg-RX-API-DMAC7.html)
IL (1) IL276875A (cg-RX-API-DMAC7.html)
MX (1) MX2020008916A (cg-RX-API-DMAC7.html)
PH (1) PH12020551323A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202008149RA (cg-RX-API-DMAC7.html)
WO (1) WO2019169015A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202005320B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
US10189899B2 (en) 2013-07-23 2019-01-29 Biocon Limited Use of a CD6 binding partner and method based thereon
KR102514528B1 (ko) 2016-10-21 2023-03-27 바이오콘 리미티드 루푸스 치료를 위한 단일클론항체 및 이의 치료방법
US20230151107A1 (en) * 2020-04-04 2023-05-18 Biocon Limited Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
IL303290A (en) * 2020-12-04 2023-07-01 Equillium Inc Methods of selectively targeting cd6 high cells and decreasing activity of t eff cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
CU22584A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
AU747898B2 (en) 1997-03-03 2002-05-30 Bristol-Myers Squibb Company Monoclonal antibodies to human CD6
MY154819A (en) 2006-12-26 2015-07-31 Centro Inmunologia Molecular Pharmaceutical compositions with capacity to induce adoptosis in tumor cells for the diagnosis and treatment of the b-cell chroniclymphocytic leukemia
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
CN102559636B (zh) * 2011-12-30 2014-03-12 百泰生物药业有限公司 用于白血病和自身免疫疾病的抗体融合蛋白及其制备方法
JP6296650B2 (ja) 2013-03-13 2018-03-20 国立大学法人 筑波大学 免疫疾患に対する医薬組成物
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック, インコーポレイテッド 抗il−13/il−17二重特異性抗体及びその使用
TWI726897B (zh) 2015-07-15 2021-05-11 日商協和麒麟股份有限公司 與人類crth2特異性結合之抗體
US10562975B2 (en) 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
IL266087B2 (en) * 2016-10-18 2024-02-01 Biocon Ltd Use of itolizumab to reduce phosphorylation of cd6

Similar Documents

Publication Publication Date Title
EP2500361B1 (en) Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
EP4198055A1 (en) Antibody of il-11 and use thereof
JP2022023051A (ja) 瘻孔を伴うクローン病の治療用ベドリズマブ
US20150183871A1 (en) Antibodies against the rgm a protein and uses thereof
US9067996B2 (en) Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
CN110624107A (zh) 通过施用il-4r拮抗剂治疗或预防哮喘的方法
JP2017501711A (ja) 二重特異性抗体
JP2014511179A5 (cg-RX-API-DMAC7.html)
JP2017507945A5 (cg-RX-API-DMAC7.html)
HUE031923T2 (en) Antibody molecules that exhibit binding specificity for human IL-13
JP2024541680A5 (cg-RX-API-DMAC7.html)
JP2019513726A5 (cg-RX-API-DMAC7.html)
EP3858857A1 (en) An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
EP2986640B1 (en) Humanized antibody against interleukin-20 and treatment for inflammatory diseases
WO2020034941A1 (zh) 抗IL-1β的抗体、其药物组合物及其用途
JP2021511024A5 (cg-RX-API-DMAC7.html)
TW202321303A (zh) 抗pla2r自體抗體媒介膜性腎病變之治療
TW202235435A (zh) 抗cd38抗體及其用途
US20260008865A1 (en) Antibodies, compositions, and methods of treatment
CN118076640A (zh) 抗-pla2r自身抗体介导的膜性肾病的治疗
EP4511396A1 (en) Antibodies and methods targeting interleukin-19
RU2020130563A (ru) Антитела к cd6 для лечения тяжелой астмы
TH1901006538A (th) การบำบัดโรคหอบหืดด้วยแอนติบอดี้ต้าน tslp
NZ619873A (en) Methods and compositions for treating asthma using anti-il-13 antibodies
HK1137182B (en) Antibodies to receptor of advanced glycation end products (rage) and uses thereof